Canine T‐cell lymphoma (TCL) encompasses a heterogeneous group of diseases with variable clinical presentation, cytomorphology, immunophenotype, and biologic behaviour. The most common types of TCL in dogs involving peripheral lymph nodes include indolent T‐zone lymphoma (TZL) and biologically aggressive peripheral T‐cell lymphoma (PTCL). TCL phenotypes can be categorized by expression of the surface antigen molecules CD4 and CD8. The majority of TCL cases are CD4⁺, with far fewer cases being CD8⁺ or CD4⁻ CD8⁻. The clinical features of CD4⁺ TCLs have been previously described. The less common TCL phenotypes, however, are poorly characterized with little to no information about prognosis. In this retrospective study, we describe and correlate the presenting clinical signs, flow cytometry, and outcomes of 119 dogs diagnosed with nodal, non‐TZL, CD8⁺ or CD4⁻ CD8⁻ TCL by flow cytometry. Skin lesions present at the time of diagnosis were more commonly observed in the CD8⁺ TCL group. Mediastinal enlargement and/or hypercalcemia were more commonly seen in the CD4⁻ CD8⁻ TCL group. Dogs with either CD8⁺ or CD4⁻ CD8⁻ TCLs had aggressive clinical disease with median overall survival (OS) times of 198 days and 145 days, respectively. In both groups, neoplastic cell size determined by flow cytometry ranged from small to large, and large cell size was associated with shorter OS times (median OS = 61 days). Cases classified as small cell had a median OS of 257 days. Expression levels of major histocompatibility complex (MHC) class II and CD5 were highly variable among cases but were not prognostically significant in this group of patients.

中文翻译：

---

流式细胞术将犬淋巴结T细胞淋巴瘤的临床特征分为CD8 +或CD4-CD8-。

犬T细胞淋巴瘤（TCL）涵盖了一组异质性疾病，其临床表现，细胞形态，免疫表型和生物学行为均不相同。涉及外周淋巴结的狗中最常见的TCL类型包括惰性T区淋巴瘤（TZL）和生物学侵袭性外周T细胞淋巴瘤（PTCL）。TCL表型可以通过表面抗原分子CD4和CD8的表达进行分类。大多数TCL病例是CD4 ⁺，远用较少的情况下是CD8 ⁺或CD4 ^- CD8 ^- 。CD4 ⁺的临床特征先前已经描述了TCL。然而，不太常见的TCL表型的特征很差，几乎没有关于预后的信息。在这项回顾性研究中，我们描述并关联了通过流式细胞术诊断为淋巴结，非TZL，CD8 ⁺或CD4 ^- CD8 ^- TCL的119只狗的临床体征，流式细胞仪和结果。诊断时出现的皮肤病变在CD8 ⁺ TCL组中更为常见。在CD4 ^- CD8 ^- TCL组中更常见于纵隔增大和/或高钙血症。患有CD8 ⁺或CD4 ⁻ CD8 ^−的狗TCL具有侵略性临床疾病，中位总生存（OS）时间分别为198天和145天。在两组中，通过流式细胞术确定的赘生性细胞大小从小到大，并且大细胞大小与较短的OS时间相关（中位OS = 61天）。分类为小细胞的病例的中位OS为257天。在这种情况下，主要组织相容性复合物（MHC）II类和CD5类的表达水平差异很大，但在预后上并不显着。